isoray inc (AAJ) Snapshot

IsoRay, Inc. announced that it has entered into an exclusive international distribution agreement with IASIS Medical for the sale of IsoRay's complete product line in Greece. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic (gyn) cancer. IASIS Medical is ideally suited to support IsoRay's products, which utilize the uniqueness of IsoRay's Cs-131 isotope to attack cancers in the prostate and other body sites, such as brain cancer, head and neck cancer, lung cancer and gyn cancers, while providing patients with a better quality of life than many competing treatments, in Greece. International distributor opportunities aid IsoRay in obtaining increasing recognition in the world marketplace for cancer treatments as more physicians and surgeons internationally are made aware of the power of Cesium through published studies.

IsoRay, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2013. For the quarter, the company reported product sales of $1,251,478 against $1,317,371 a year ago. Operating loss was $824,120 against $762,859 a year ago. Net loss applicable to common shareholders was $717,695 or $0.02 per basic and diluted share against $555,544 or $0.02 per basic and diluted share a year ago. For the nine months, the company reported product sales of $3,283,167 against $3,759,443 a year ago. Operating loss was $3,046,381 against $2,657,317 a year ago. Net loss applicable to common shareholders was $2,871,006 or $0.08 per basic and diluted share against $2,291,920 or $0.08 per basic and diluted share a year ago.

IsoRay, Inc. announced that they will report Q3, 2013 results on May 15, 2013